Key facts
- This page summarizes Gina Mazzariello's Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 14 Sep 2026, 16:00.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Sale
Sale
Additional SEC filing notes
Footnote F1
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person.
Footnote F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.34 to $33.26. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.